NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+2.82%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.45B
AUM Growth
+$1.45B
(-10%)
Cap. Flow
-$42.9M
Cap. Flow
% of AUM
-2.96%
Top 10 Holdings %
Top 10 Hldgs %
63.01%
Holding
41
New
5
Increased
1
Reduced
8
Closed
6
Top Buys
| 1 |
Edgewell Personal Care
EPC
|
$116M |
| 2 |
Viridian Therapeutics
VRDN
|
$19.3M |
| 3 |
ArriVent BioPharma
AVBP
|
$19.2M |
| 4 |
Metagenomi
MGX
|
$18.3M |
| 5 |
Kyverna Therapeutics
KYTX
|
$17.4M |
Top Sells
| 1 |
TSMC
TSM
|
$73.9M |
| 2 |
Edgewise Therapeutics
EWTX
|
$66.4M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$21.3M |
| 4 |
SPRB
Spruce Biosciences, Inc. Common Stock
SPRB
|
$19.7M |
| 5 |
Salesforce
CRM
|
$15.2M |
Sector Composition
| 1 | Healthcare | 45.12% |
| 2 | Technology | 24.54% |
| 3 | Financials | 13.03% |
| 4 | Consumer Staples | 7.98% |
| 5 | Communication Services | 3.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ASML
ASML
$292B
| $177M | 12.22% | 182,536 -15,224 | -8% | -$14.8M |
|
2
Brookfield
BN
$98.3B
| $162M | 11.21% | 3,880,230 | – | – |
|
|
3
Salesforce
CRM
$245B
| $145M | 9.98% | 480,160 -50,340 | -9% | -$15.2M |
|
|
4
Edgewell Personal Care
EPC
$1.12B
| $116M | 7.98% | +6,344,430 | New | +$116M |
|
5
Corcept Therapeutics
CORT
$7.35B
| $60.7M | 4.19% | 2,411,362 | – | – |
|
6
Vaxcyte
PCVX
$4B
| $57.7M | 3.98% | 845,000 | – | – |
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $51.4M | 3.55% | 1,098,600 -1,400 | -0.1% | -$65.5K |
|
8
Cable One
CABO
$909M
| $50.1M | 3.46% | 118,403 | – | – |
|
9
LanzaTech
LNZA
$49.1M
| $48.9M | 3.38% | 15,814,845 | – | – |
|
10
4D Molecular Therapeutics
FDMT
$288M
| $44.6M | 3.08% | 1,400,000 -100,000 | -7% | -$3.19M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $39.3M | 2.71% | 450,000 | – | – |
|
12
Mirum Pharmaceuticals
MIRM
$3.71B
| $37.7M | 2.6% | 1,500,000 | – | – |
|
13
Insmed
INSM
$28.8B
| $36.3M | 2.51% | 1,339,304 | – | – |
|
14
Alibaba
BABA
$322B
| $36.2M | 2.5% | 500,827 | – | – |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $34M | 2.35% | 358,626 -500 | -0.1% | -$47.4K |
|
16
Apple
AAPL
$3.45T
| $31.4M | 2.16% | 182,960 -38,500 | -17% | -$6.6M |
|
17
Amicus Therapeutics
FOLD
$2.34B
| $29.5M | 2.03% | 2,500,000 | – | – |
|
18
Rocket Pharmaceuticals
RCKT
$354M
| $28.3M | 1.95% | 1,050,000 | – | – |
|
|
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
| $27.9M | 1.92% | 1,250,000 | – | – |
|
20
Pharvaris
PHVS
$1.39B
| $27M | 1.86% | 1,168,030 -371,295 | -24% | -$8.58M |
|
|
VERV
21
DELISTED
Verve Therapeutics
VERV
| $26.6M | 1.83% | 2,000,000 | – | – |
|
22
Brookfield Asset Management
BAM
$97B
| $26.4M | 1.82% | 627,207 | – | – |
|
23
Lexeo Therapeutics
LXEO
$259M
| $25.7M | 1.77% | 1,638,298 +330,469 | +25% | +$5.18M |
|
|
24
Viridian Therapeutics
VRDN
$1.5B
| $19.3M | 1.33% | +1,100,000 | New | +$19.3M |
|
|
25
ArriVent BioPharma
AVBP
$776M
| $19.2M | 1.33% | +1,077,140 | New | +$19.2M |
|